Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Servier-Acq-Edgewise

More Like This

PR Newswire associated0

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

PR Newswire associated0

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

PR Newswire associated0

Servier completes the acquisition of Day One Biopharmaceuticals

PR Newswire associated0

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

PR Newswire associated0

The Department of Health - Abu Dhabi provides gene therapy for Duchenne Muscular Dystrophy for the first time in Abu Dhabi and outside the US

PR Newswire associated0

ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence